平均减重超20%！替尔泊肽：降糖、减重“双管齐下”

Core Viewpoint - The article discusses the efficacy of Tirzepatide, a dual GIP and GLP-1 receptor agonist, in weight loss and glycemic control, highlighting its clinical trial results and potential advantages over existing treatments [5][7]. Weight Loss - Tirzepatide has shown significant weight loss results in clinical trials, with the SURMOUNT-1 study indicating an average weight reduction of 15.4% (5mg), 19.9% (10mg), and 22.9% (15mg) compared to a mere 2.1% in the placebo group after 176 weeks [8] - The SURMOUNT-2 study confirmed that higher doses of Tirzepatide led to an average weight loss of 15.7% (15.6kg) in obese patients with type 2 diabetes, with 81.6% and 86.4% of patients in the 10mg and 15mg groups losing over 5% of their body weight, respectively [10] - In the SURMOUNT-3 trial, patients experienced a weight loss of up to 26.6% after 12 weeks of lifestyle intervention and 72 weeks of Tirzepatide treatment [12] - The SURMOUNT-4 trial reported an average weight loss of 21.1% during the initial 36 weeks, followed by an additional 6.7% during the subsequent 52 weeks, totaling a 26.0% weight loss over 88 weeks [12] - The SURMOUNT-5 trial demonstrated that Tirzepatide outperformed an active comparator, with participants losing an average of 50.3 pounds (22.8kg) compared to 33.1 pounds (15.0kg) in the control group, indicating a 47% greater weight loss [12] Glycemic Control - Type 2 diabetes (T2DM) is a rapidly increasing global health issue, with approximately 463 million adults affected, primarily by T2DM [13] - Traditional diabetes medications often lead to weight gain and have limitations, prompting the need for new treatments like GLP-1 receptor agonists [15] - Tirzepatide has been shown to significantly improve insulin sensitivity and beta-cell function in T2DM patients, with HbA1c levels decreasing by an average of 2.0%-2.5% [16] - In head-to-head studies, Tirzepatide demonstrated superior HbA1c reduction compared to Semaglutide, with a reduction of 2.46% in the 15mg group versus 1.86% in the Semaglutide group [16] Dual Mechanism Benefits - Tirzepatide's dual action on GIP and GLP-1 receptors provides enhanced weight loss and glycemic control compared to single receptor agonists like Semaglutide [17] - GIP plays a crucial role in insulin secretion, and restoring its function is vital for diabetes treatment [17] - Research indicates that GIP receptor agonists can synergistically enhance the effects of GLP-1, improving both weight loss and glycemic control [20]